Search results for " OSTEOPOROSIS"

showing 10 items of 92 documents

IL PAZIENTE ANZIANO CON FRATTURA DI FEMORE: VALUTAZIONE E SUPPORTO NUTRIZIONALE

2013

Osteoporosis in the elderly population is a major health problem worldwide, because it is associated with fragility fractures with consequent financial burden for health systems. Europe and North America are the regions where half of all hip fractures among elderly people occurred today, with Scandinavian countries reporting the highest incidence worldwide. Undernutrition, particularly protein malnutrition, is frequent in elderly with osteoporotic hip fracture, although, the role of dietary protein intake in osteoporosis remains controversial. Poor nutritional status is associated with higher comorbidity indices, mortality and readmissions in patients with femoral fracture. Another crucial …

Settore MED/09 - Medicina Internahip fracture fragility fracture frailty osteoporosis malnutrition older adult aging
researchProduct

Role of genetic predisposition as a risk factor for osteoporosis.

2005

Settore MED/09 - Medicina Internarisk factorgenetic predisposition; risk factor; osteoporosisgenetic predispositionosteoporosis
researchProduct

BONE LOSS I INFLAMMATORI BOWEL DISEASE: OUR MULTICENTRIC STUDY

2011

Patients with inflammatory bowel disease are at increased risk of developing disorder in bone and mineral metabolism. The study was aimed to determine if inflammatory bowel disease (IBD) is a risk factor for osteoporosis in 103 adult patients. We included 103 IBD patients, 67 patients with Crohn's disease (CD) and 36 with ulcerative colitisi (UC). Bone mineral density was measured by dual-energy X-ray absorptiometry. we used T score to express bone loss (osteopenia: -25SD 2 years) and active disease would be risk of bone mineral loss in IBD.

Settore MED/18 - Chirurgia GeneraleCrohn's disease Osteoporosis dexa inflammatory bowel disease ulcerative colitis.
researchProduct

Evolution and healing of fragility fractures of the proximal femur

2014

After a traumatic fracture a physiological process begins to heal the fracture. The steps of the process are inflammation, granulation, formation of fibrous callus and finally bone. There are many factors that may influence the healing of the fracture: adequate blood supply, good contact between bone fragments, good stability of the fracture, general health, age, smoking, related pathology, use of drugs, etc. In elderly patients the variations in bone structure and healing processes have a negative influence on fracture healing. Fragility fractures require careful placement of the implants to reduce the risk of failure of osteosynthesis. Appropriate surgical devices and facilitation factors…

Settore MED/33 - Malattie Apparato LocomotoreFemur Osteoporosis Fracture Healing
researchProduct

Differential diagnosis of vascular necrosis of the femoral head (AVN) and transient hip osteoporosis (THO): role of MRI

2014

Settore MED/33 - Malattie Apparato Locomotoreavascular necrosis femoral head transient hip osteoporosis
researchProduct

Treatment adherence and QoL with intermittent PTH therapy: Results from a multicentre Italian study after 6 months

2011

This ongoing multicentre study was carried out to investigate the adherence to intermittent parathyroid hormone treatment and the effect on QoL in a typical Italian population eligible for drug reimbursement (i.e. a new vertebral or hip fracture following at least one year of anti-resorptive therapy or three severe vertebral fractures or two severe and one femur fracture). 204 female patients (mean age: 72.6±8.3) were enrolled between March 2008 and April 2009. These patients were treated with PTH (PTH 1–34 or PTH 1–84) according to Italian legislation. Here, we report the results obtained at month 6.

Settore MED/34 - Medicina Fisica E RiabilitativaQol PTH therapy osteoporosis vertebral fractures
researchProduct

Prevalence of Vertebral Fractures in Osteoporotic HIP Fractured Patients: The Focus Study

2015

Settore MED/34 - Medicina Fisica E Riabilitativavertebral fractures hip fractures osteoporosis rehabilitation
researchProduct

TREATMENT WITH DAILY SUBCUTANEOUS TERIPARATIDE (1-34) COMPARED WITH DAILY SUBCUTANEOUS PARATHYROID HORMONE (1-84) IN WOMEN WITH SEVERE POSTMENOPAUSAL…

2008

TERIPARATIDE PARATHYROID HORMONE OSTEOPOROSIS BONE TURNOVER BMDSettore MED/09 - Medicina Interna
researchProduct

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020

2020

The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference—held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)—after the newest recommendations (2020) on MRONJ were published by two scientific societies (Italian Societies of Maxillofacial Surgery and Oral Pathology and Medicine, SI…

bisphosphonateOral SurgeonHealth Toxicology and Mutagenesislcsh:MedicineMRONJantiangiogenic agents; antiresorptive drugs; bisphosphonates; cancer; denosumab; dentistry; MRONJ; oral surgery; osteoporosis; prevention models; bisphosphonate-associated osteonecrosis of the jaw; bone density conservation agents; diphosphonates; humans; Italy; quality of life0302 clinical medicineprevention modelCancerantiangiogenic agentsdentistryBone Density Conservation AgentsDiphosphonatesConference ReportBisphosphonatesAntiresorptive DrugsDenosumabItaly030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabmedicine.drugoral surgerymedicine.medical_specialtyOral surgery03 medical and health sciencesOral surgeryAntiangiogenic agentsOral and maxillofacial pathologymedicinecancerHumansantiangiogenic agentantiresorptive drugsIntensive care medicinePrevention modelsbisphosphonatesantiresorptive drugAntiangiogenic agentsbusiness.industrylcsh:RPublic Health Environmental and Occupational Healthdenosumab030206 dentistrymedicine.diseaseosteoporosisAntiresorptive drugsDentistryOsteoporosisprevention modelsbusinessAntiangiogenic agents; Antiresorptive drugs; Bisphosphonates; Cancer; Denosumab; Dentistry; MRONJ; Oral surgery; Osteoporosis; Prevention models
researchProduct

Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing’s Disease

2020

Purpose: To evaluate circulating irisin levels in patients with active and controlled Cushing’s disease (CD). Design: Forty-four patients with CD evaluated during the active phase and after 12 months of biochemical remission and 40 controls were recruited. Methods: Phenotypic, anthropometric, hormonal and metabolic parameters, including insulin sensitivity estimation by homeostatic model of insulin resistance, Matsuda index and oral disposition index and circulating irisin levels were evaluated. Results: Patients with active CD showed lower irisin levels compared to controls (p<0.001) and controlled CD (p<0.001). The independent variables significantly associated with irisin were wais…

irisin osteoporosis myopathy Cushing’s diseaseCushing’s diseaseirisinosteoporosisSettore MED/13 - EndocrinologiaOriginal ResearchmyopathyDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
researchProduct